Call for Abstract
8th World Congress on Antibiotics, Antimicrobials & Antibiotic Resistance, will be organized around the theme “ Innovative and Approaches in the field of Antibiotics and Antimicrobials”
Antimicrobials 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Antimicrobials 2020
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Less common side effects of antibiotics include:
- Track 1-1Common Triggers of Drug Allergies
- Track 1-2Diagnosing Drug Allergies
- Track 1-3Drug Allergy Management and Treatment
- Track 1-4Antibiotics to prevent infection
- Track 1-5Antibiotic Therapy
- Track 1-6Weakened Immune System
- Track 1-7Dental Antibiotic Prophylaxis
The introduction of penicillin considered the beginning of the so-called “golden era” of antibiotics. Between 1940 and 1962, most of the antibiotic classes we use as medicines today were invented and recommended to the market. Each class typically consists of several antibiotics that have been discovered over time or are modified versions of previous types. Such as different penicillins and cephalosporins.
- Track 2-1Pre-Antibiotic Era
- Track 2-2Foundation of the Antibiotic Era - Antibiotic Resistance
- Track 2-3Improvement of Antimicrobials
- Track 2-4Environmental Resistome
In fact, using antibiotics for viral infections can raise the risk for antibiotic resistance, lower the options for future treatments if an antibiotic is needed, and put a patient at risk for side effects and extra cost due to irrelevant drug treatment.
- Track 3-1Antibiotics for UTI Treatment
- Track 3-2Pertussis (Whooping cough)
- Track 3-3Pneumonia – Child & Adult
- Track 3-4Ear, nose and throat
- Track 3-5Common Cold and Runny Nose
- Track 3-6Ear Infection
- Track 3-7Influenza (Flu)
- Track 3-8Urinary Tract Infection
The drug development process is as follows: inventing or discovering a compound, preclinical trials on microbes and animals i.e., in-vitro, in-vivo, clinical trials involving patients by clinical research management. Social responsibility and ethics should walk hand in hand with research for good clinical research management.
- Track 4-1Preclinical- Clinical Phase
- Track 4-2New drug application
- Track 4-3Novel initiatives to boost development
Infectious diseases are usually stretch out from one individual to a distinct, for instance through contact with bodily fluids, by aerosols (through coughing and sneezing), or via a vector, for instance a dipteran. Infectious diseases square measure one amongst the well-known causes of death worldwide. Several diseases turn into tough to regulate if the infectious agents evolve resistance to usually used medication. Scientists, square measure presently sorting out latest approaches to treat infectious diseases, specialize in precisely however the pathogens modification and drug resistance evolves.
- Track 5-1Fungal infectious diseases
- Track 5-2Viral Infectious diseases
- Track 5-3Bacterial infectious diseases
- Track 5-4Anthrapod infectious diseases
- Track 5-5Parasital infectious diseases
- Track 5-6Infectious Agents
With the onset of new and emerging technologies, we are poised to harvest novel drugs from the so-called 'uncultivable' microbes. Multidisciplinary ways of linking different technologies can assist and reform drug discovery from uncultivable microbes and inspect the current cramp of technologies and scenarios to swamped such constraints that might further expand the promise of drugs from environmental microbes.
- Track 6-1Novel species discovery
- Track 6-2Micos from different areas (patients, geographical locations)
- Track 6-3Compounds undergoing clinical evaluation
- Track 6-4Geneticlly modified organisms
A drug interaction is a change in the side effects of a drug caused by contemporary administration with food, beverage, supplement, or another drug. There are many causes of drug interactions. For example, one drug may change the pharmacokinetics of another. Alternately, drug interactions may result from competition for a single receptor or signaling pathway. The risk of drug-drug interaction increases with the number of drugs used. Over a third (36%) of the elderly in the U.S. regularly uses five or more medications or supplements, and 15% are at the potential risk of a significant drug-drug interaction.
- Track 7-1Drug-Drug interaction
- Track 7-2Pharmacodynamical interactions
- Track 7-3Pharmacokinetic interactions
- Track 7-4Herb-drug interactions
Further categorization is based on their target specificity. Narrow-spectrum antibiotics focus on specific types of bacteria (gram-negative or gram-positive), whereas antibiotics affect a wide range of bacteria. Following a 40-year break in discovering new types of antibacterial compounds, four new classes of antibiotics have been brought into clinical use in the late 2000s and early 2010s: cyclic lipopeptides (like as daptomycin), glycylcyclines (like as tigecycline), oxazolidinones (like as linezolid), and lipiarmycins (like as fidaxomicin).
- Track 8-1Penicillins
- Track 8-2Tetracycline
- Track 8-3Cephalosporins
- Track 8-4Quinolones
- Track 8-5Lincomycins
Resistance to antibiotics can be produced by four general mechanisms:
- The inactivation or modification of the antibiotic;
- An alteration in the aim site of the antibiotic that decreases its binding capacity;
- The adjustment of metabolic pathways to circumvent the antibiotic effect;
The decreased intracellular antibiotic accumulation by decreasing permeability and/or increasing active efflux of the antibiotic.
- Track 9-1Genetic Basis Of Antimicrobial Resistance
- Track 9-2Mechanistic Basis Of Antimicrobial Resistance
- Track 9-3Antibiotic Modification or Degradation
- Track 9-4Target Modification/Bypass/Protection Mechanisms
Increasing endeavors are being witnessed toward the improvement of advanced products. According to the data published by the Pew Charitable Trust, in March 2016, around 37 promising molecules were being examined within the U.S. market. The majorities of these are in phase II clinical trials and are anticipated to hit the market between 2018 - 2020. Furthermore, supportive government legislation, like the Generating Antibiotics Incentives Now (GAIN) Act is expected to expedite the approval process. GAIN Act has provisions that facilitate the development of therapy against antibiotic-resistant pathogens.
- Track 10-1Role of antibiotics in nature
- Track 10-2Role of antibiotics as signaling molecules
- Track 10-3Antibiotics in virulence
- Track 10-4Antibiotics in SOS and DNA repair gene expression
Antibiotics are medicines used to avoid and treat bacterial infections. Antibiotic resistance occurs when bacteria transform in response to the utilization of these medicines. Bacteria, not humans or animals, become antibiotic-resistant. These bacteria may infect humans and animals, and the infections they cause are harder to treat than those caused by non-resistant bacteria. Antibiotic resistance leads to higher medical costs, prolonged hospital stays, and expanded mortality. The world immediately needs to transform the way it prescribes and uses antibiotics. Even if new medicines are developed, without behavior transformed, antibiotic resistance will continue a major threat. Behavior transformations must also include actions to reduce the spread of infections through vaccination, hand washing, practicing safer sex, and good food hygiene.
- Track 11-1Clinical significance
- Track 11-2Veterinary medicine
- Track 11-3Natural occurrence
- Track 11-4Water pollution
Antibiotic resistance is now among every part of the world and its stirring everyone irrespective of the age. When infections become resistant to first-line drugs, high costly therapies must be needed. A longer duration of illness and treatment, often in hospitals, increases health care costs as well as the financial burden on families and societies. To guidance prevent the improvement of current and future bacterial resistance, it is necessary to recommend antibiotics according to the principles of antimicrobial stewardship, like specifying antibiotics only when they are useful.
- Track 12-1Antimicrobial resistance in microbes
- Track 12-2Common bovine infections and their treatment
- Track 12-3Factors associated with antimicrobial resistance in animals
- Track 12-4Molecular mechanisms of the resistance against major antimicrobial drugs
Resistant bacteria may be conveyed to humans through the foods we eat. Some bacteria have turned resistant to higher than one sort of antibiotic, which accomplishes it more difficult to treat the infections they cause. Preserving the efficiency of antibiotic drugs is vital to cushioning human and animal health.
- Track 13-1Antibiotics in food Industry
- Track 13-2Antibiotics in agriculture
- Track 13-3Antibiotics in veterinary
- Track 13-4Antibiotics in aquaculture
The compelling importance of the fact that all healthcare personnel should take ownership of the need to specify accordingly and to practice effective infection control. A realization that antibiotics may not be competent for the tasks required of them and eventually, with widespread resistance, may be incapable of the task they do today.
- Track 14-1Growth Promoters in Animals
- Track 14-2Antibiotic Use in Aquaculture
- Track 14-3Domestic Uses
- Track 14-4Antibiotics as tools in molecular biology
The growth of an existing drug molecule from an ordinary form to a novel delivery structure can significantly develop its performance in terms of patient compliance, efficacy, and safety. These days, drug delivery organizations are engaged in the improvement of numerous platform technologies to get ambitious advantages, extend patient life, and increase the market share of their products. Formerly a compound has displayed its value in these tests; it will begin the process of drug development prior to clinical trials.
- Track 15-1Policies to stimulate drug development and discovery
- Track 15-2Role of computational biology
- Track 15-3Ligand binding studies, CAD & CAM
- Track 15-4Transport (simulation studies)
- Track 15-5Molecule mediating transport- Sustained Drug Delivery
- Track 15-6Nanotechnology
In advanced countries, public health measures like excrement treatment, vaccination programs, sanitation and access to good medical care-including a wide range of antibiotics-have essentially disposed of historical diseases like tuberculosis, diphtheria and whooping cough.
- Track 16-1Resistance and re-emerging theories
- Track 16-2Medication procedures
- Track 16-3Molecular mechanism of resistance
- Track 16-4New drugs for emerging diseases
This helps to provide regulatory authorities and industry strategists a better perspective on which to base their decisions. BCC Research published a report about this topic in 2002. Since then, the market has witnessed dramatic changes in terms of technology, investment, and regulatory trends, which are captured in this report.
- Track 17-1The global economic scenario of antibiotic resistance
- Track 17-2Antibiotic discovery and supremacy
- Track 17-3Photo-deposited silver coatings
- Track 17-4Photodynamic Combination therapy
- Track 17-5Functional Silver Nano composites
- Track 17-6Engineered monolayer portion
Research includes the epidemiology of both Gram-negative and Gram-positive infections, genetic mechanisms of resistance, evolution and transmission in the hospital setting, as well as the community, and antimicrobial stewardship.
- Track 18-1Causes of the antibiotic resistance crisis
- Track 18-2Antibiotic-resistant bacterial infections
- Track 18-3The clinical and economic burden of antibiotic resistance